Liu Shaoluan is really a shrewd investor, and he can be described as a crocodile in the world, and he will bite it tightly once he enters the market. According to the 2019 annual report, Liu Shaoluan bought 6.89 million shares of Buchang Pharmaceutical, thus becoming the company's tenth largest shareholder. Although Buchang Pharmaceutical's stock price has been **, he has not flinched, but has continued to increase his investment, and has never **.
Today, Liu Shaoluan has held a large number of 25.3 million shares, worth more than 400 million, becoming the third largest shareholder of Buchang Pharmaceutical. Buchang Pharmaceutical's stock price is constantly **, and Liu Shaoluan is buying all the way and holding it unswervingly, because in his eyes, Buchang Pharmaceutical is expected to become the next Pien Tze Huang! He is eager to recreate Wang Fuji's success in Pien Tze Huang.
In fact, Buchang Pharmaceutical may not be as brilliant as Pien Tze Huang, but compared with Ejiao, Buchang Pharmaceutical also has the power to fight. The company is a leading enterprise in the field of cardiovascular and cerebrovascular Chinese patent medicines, and has exclusive patented varieties of traditional Chinese medicine such as Naoxintong capsules, Wenxin granules, and Danhong injection. These products have a leading market share in the cardiovascular and cerebrovascular field, with an annual turnover of more than 10 billion, and the scale is huge, which can be seen from the market's recognition of Buchang Pharmaceutical.
Buchang Pharmaceutical focuses on the field of cardiovascular and cerebrovascular drugs, which is also one of the main benefits of the aging society. From the perspective of diseases, the most promising investment direction in the pharmaceutical industry is cardiovascular and cerebrovascular, followed by cancer. Buchang Pharmaceutical is on this high-quality track, and the company's revenue has reached 15 billion yuan, which is in a leading position in the traditional Chinese medicine industry. Once profits recover, Buchang Pharmaceutical's prospects will be limitless. In this battle, Liu Shaoluan is likely to win again!